SecBot SecBot
144 ·Filed Jul 30, 2026

TRDA

Entrada Therapeutics, Inc.
BEARISH
Impact 5/10
Horizondays Processed3mo ago SEC0001674324-26-000006
Actionable Insight ▼ Bearish

Monitor for actual execution of the sale via subsequent Form 4 filings. If 5AM Ventures completes this sale, it could mark the start of a distribution phase, potentially weighing on the stock. Given the stock's historical volatility, traders should watch for further insider selling or additional 144 filings from other affiliates.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.79
T+0 close · Jul 30, 2026 · via day close
Latest settled
−30.04%
T+60 · $4.75
Vs SPY
−32.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 31 $6.79entry
  2. T+1 · 4mo ago +6.92%α +5.50% · $7.26
  3. T+5 · 3mo ago +1.18%α −2.33% · $6.87
  4. T+20 · 3mo ago +3.09%α +0.10% · $7.00
  5. T+60 · 22d ago −30.04%α −32.50% · $4.75
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

5AM Ventures V, L.P., an early venture investor and affiliated stockholder of Entrada Therapeutics, filed a Form 144 notice of intent to sell 331,156 shares of common stock, valued at approximately $2.17 million. The proposed sale represents about 0.85% of shares outstanding and signals potential portfolio distribution by a long-term holder.

Key Facts

  • 5AM Ventures V, L.P. proposes to sell 331,156 shares of Entrada Therapeutics common stock.
  • Estimated market value of the proposed sale is $2,169,072.
  • Shares were acquired on October 12, 2016 via venture financing investment.
  • The sale is to be executed through Goldman Sachs & Co. LLC.
  • Filing date is July 30, 2026; the sale is not yet completed.

Financial Impact

Proposed sale of 331,156 shares (~0.85% of 38.8M shares outstanding) valued at ~$2.17M, representing a modest but notable reduction by a key early investor.

dilutioninsider selling pressure

Risk Factors

  • Further selling by 5AM Ventures or other early investors could increase supply and pressure the stock.
  • The intent-to-sell filing may signal reduced confidence from a long-term holder, potentially spooking retail and institutional investors.
  • Entrada Therapeutics is a small-cap biotech with volatile price action; the sale could amplify downside moves.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (TRDA), Batch item 10001674324-26-000006
Document: 0001674324-26-000006-index.html0001674324-26-000006
Document: 0001674324-26-000006.txt0001674324-26-000006
144 Filing (TRDA), Batch item 40001674324-26-000006
Document: 0001674324-26-000006-index.html0001674324-26-000006
Document: 0001674324-26-000006.txt0001674324-26-000006

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026